HalioDx is Now Part of Veracyte! Learn About HalioDx Read the Press Release
HalioDx is Now Part of Veracyte! Learn About HalioDx Read the Press Release
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
- Findings from Analysis Evaluating Test In Newly Diagnosed, Clinically High-Risk Disease to be Highlighted in ASTRO Press Program - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 14, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced that new data further validating the clinical utility of the
View HTML
Toggle Summary New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 13, 2021-- Veracyte, Inc ., (Nasdaq: VCYT) announced today the publication of new data demonstrating that the company’s Decipher Bladder genomic classifier accurately identifies bladder tumors that are most likely to respond to chemotherapy prior
View HTML
Toggle Summary Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 12, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Tuesday, November 9 . Company management will host a conference call and webcast to
View HTML
Toggle Summary New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
Findings to be shared in oral presentation at CHEST Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic
View HTML
Toggle Summary Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
Company begins making novel, noninvasive test available to limited number of clinical sites to support more timely, accurate lung nodule diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that new expanded clinical validation data
View HTML
Toggle Summary New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
- Expanded clinical validation data demonstrate Percepta Nasal Swab test performance across nodule sizes and cancer stages in early lung cancer assessment - - Findings reinforce value of Percepta GSC and Envisia GC in clinical decision-making and patient care - SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that its Decipher ® Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines for Oncology to guide
View HTML
Toggle Summary Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 1, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced that it has appointed Joshua Klopper , M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recognized endocrinologist who
View HTML
Toggle Summary Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 31, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global diagnostics company, today announced that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the Morgan Stanley Virtual
View HTML
Toggle Summary Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 23, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global diagnostics company, announced today that it has been awarded a Top Workplaces honor by the Bay Area News Group for the eighth consecutive year. The annual award is based solely on employee
View HTML